HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pirk, J. Articles by Firt, P. Search for Related Content PubMed PubMed Citation Articles by Pirk, J. Articles by Firt, P.

The Annals of Thoracic Surgery, Vol 42, 312-314, Copyright © 1986 by The Society of Thoracic Surgeons

ARTICLES

Improved patency of the aortocoronary bypass by antithrombotic drugs

J Pirk, J Vojacek, J Kovac, J Fabian and P Firt

A total of 1,017 bypasses were performed in 442 patients operated on in our department between January 1, 1981, and May 30, 1984. The overall early postoperative graft patency rate in our hospital was 91.5%. About 10% of the grafts had a flow rate of 40 ml/min or less, measured intraoperatively, and most occluded grafts were in this group. This article presents our experience with low-flow bypasses whose patency rates we attempted to improve. Patients with aortocoronary bypasses (ACBs) and with intraoperative blood flow rates of 40 ml/min or less were divided into two groups. The treated group was given, from day 0 onward, a 500-mg dose of acetylsalicylic acid twice a day and a 75-mg dose of dipyridamole three times a day. The control group was given no medication. Control coronary arteriography was performed at one month and then at one year after the operation. One month postoperatively, 34 out of 41 ACBs in the treated group were patent; in the control group, only 17 out of 37 were patent (p less than .001). One year after the operation, 24 out of 37 ACBs in the treated group were patent, whereas in the control group only 8 out of 38 ACBs were patent (p less than .001). We conclude that antiplatelet drugs have a beneficial effect on the short-term and long-term patency of ACBs.

This article has been cited by other articles:

				R. C. Becker, T. W. Meade, P. B. Berger, M. Ezekowitz, C. M. O'Connor, D. A. Vorchheimer, G. H. Guyatt, D. B. Mark, and R. A. Harrington The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 776S - 814S. [Abstract] [Full Text] [PDF]

				P. D. Stein, H. J. Schunemann, J. E. Dalen, and D. Gutterman Antithrombotic Therapy in Patients With Saphenous Vein and Internal Mammary Artery Bypass Grafts: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest, September 1, 2004; 126(3_suppl): 600S - 608S. [Abstract] [Full Text] [PDF]

				E. Lim, Z. Ali, A. Ali, T. Routledge, L. Edmonds, D. G Altman, and S. Large Indirect comparison meta-analysis of aspirin therapy after coronary surgery BMJ, December 6, 2003; 327(7427): 1309. [Abstract] [Full Text] [PDF]

				Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy BMJ, January 15, 1994; 308(6922): 159 - 168. [Abstract] [Full Text]

				Antiplatelet Trialists Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ, January 8, 1994; 308(6921): 81 - 106. [Abstract] [Full Text]